



केन्द्रीय प्रौद्योगिकी संस्थान कोकराझार
CENTRAL INSTITUTE OF TECHNOLOGY KOKRAJHAR

Deemed to be University, MoE, Govt. of India

Kokrajhar-783370, Assam

www.cit.ac.in

No. CITK/ Estt/ Misc/ 407/ 2020/ 164

Date: 24/ 06/ 2021.

NOTIFICATION

It is for your kind information that, the Ayurvedic drug AYUSH-64 has been found useful in the treatment of asymptomatic, mild and moderate Covid-19 infection, through robust randomized clinical trials. This finding has emerged as a ray of hope for the patients of asymptomatic, mild and moderate Covid-19 infection.


AYUSH-64 is a polyherbal formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of Ayush, initially for Malaria, in the year 1980. Now, the Ministry of Ayush-Council of Scientific and Industrial Research (CSIR) collaboration has completed a randomized multi-centre clinical trial to evaluate the safety and efficacy of AYUSH-64 in the management of Covid-19. In the clinical studies, it is found useful in the treatment of asymptomatic, mild and moderate Covid-19 infection, both as an adjunct to standard care and as a standalone. AYUSH-64 is manufactured by M/S Indian Medicines Pharmaceutical Corporation Limited (IMPCL), a PSU under the Ministry of Ayush, as well as by few other companies. The drug is easily available in the market.

In this regard, you may consider the use of AYUSH-64 in the asymptomatic, mild to moderate Covid-19 patients at Isolation Centres/ Covid Care Centres / Covid Health Centres, at AYUSH Hospitals and dispensaries, and for patients in home isolation. This may be taken up in accordance with the standard Covid-19 instructions in force.

For any clarification or additional information in this matter, you are advised to kindly contact:

Dr. N. Srikanth
Director General,
Central Council for Research in Ayurvedic Sciences (CCRAS)
New Delhi – 110058
Email-id: dg-ccras@nic.in
Phone: 011-28524457




- 24/6/2021.
(Ms. Chaitali Brahma)
Registrar
Central Institute of Technology
Kokrajhar



सत्यमेव जयते

वैद्य राजेश कोटेचा

Vaidya Rajesh Kotecha

सचिव

भारत सरकार

आयुर्वेद, योग व प्राकृतिक चिकित्सा

यूनानी, सिद्ध, सोवा रिग्पा एवं होम्योपैथी (आयुष) मंत्रालय

आयुष भवन, 'बी' ब्लॉक, जी.पी.ओ. कॉम्प्लेक्स,

आई.एन.ए. नई दिल्ली-110023

SECRETARY

GOVERNMENT OF INDIA

MINISTRY OF AYURVEDA, YOGA & NATUROPATHY

UNANI, SIDDHA, SOWA-RIGPA AND HOMOEOPATHY (AYUSH)

AYUSH BHAWAN, B-BLOCK, GPO COMPLEX

INA, NEW DELHI-110023

Tel. : 011-24651950, Fax : 011-24651937

E-mail : secy-ayush@nic.in

D.O. No. S-16030/13/2020-NAM

Dated: 13th May, 2021

Dear Secretary,

I am happy to inform that the Ayurvedic drug AYUSH-64 has been found useful in the treatment of asymptomatic, mild and moderate Covid-19 infection, through robust randomized clinical trials. This finding has emerged as a ray of hope for the patients of asymptomatic, mild and moderate Covid-19 infection.

2. AYUSH-64 is a poly herbal formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of Ayush, initially for Malaria, in the year 1980. Now, Ministry of Ayush-Council of Scientific and Industrial Research(CSIR) collaboration has completed a randomized multi-centre clinical trial to evaluate the safety and efficacy of AYUSH-64 in the management of Covid-19. In the clinical studies, it is found useful in the treatment of asymptomatic, mild and moderate Covid-19 infection, both as an adjunct to standard care and as a standalone. AYUSH-64 is manufactured by M/S Indian Medicines Pharmaceutical Corporation Limited(IMPCL), a PSU under the Ministry of Ayush, as well as by few other companies. The drug is easily available in the market.

3. Ministry of Ayush feels that all Ministries/Departments who have healthcare units or functionaries under them can contribute taking the benefits of AYUSH-64 to the public. In this regard it is requested to kindly consider alerting the healthcare units/functionaries of your Ministry about this promising development. They may be requested to consider the use of AYUSH-64 in the asymptomatic, mild to moderate Covid-19 patients at Isolation Centres/Covid Care Centres/Covid Health Centres, at AYUSH hospitals and dispensaries, and for patients in home isolation in organizations/units within their jurisdiction. This can be taken up in accordance with the standard Covid-19 instructions in force.

4. For any clarification or additional information in the matter, they may be advised to contact:

Dr. N. Srikanth,
Director General,
Central Council for Research in Ayurvedic Sciences (CCRAS),
New Delhi-110058
E-mail: dg-ccras@nic.in
Phone: 011-28524457

Contd....2/-

-2-

5. In view of the above, I would request the support of the healthcare units/professionals of your Ministry/Department to reach the benefits of this medicine to as many people as possible in these difficult times.

With regards,

Yours sincerely,



(Rajesh Kotecha)

To,

All Secretaries to the Government of India.